Back to Search
Start Over
Restored Cytokine-Producing Capacities of Mucosal-associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor.
- Source :
- American Journal of Respiratory & Critical Care Medicine; 7/15/2024, Vol. 210 Issue 2, p243-245, 3p
- Publication Year :
- 2024
-
Abstract
- The article discusses how elexacaftor, tezacaftor, and ivacaftor (ETI) treatment restores the cytokine-producing abilities of mucosal-associated invariant T (MAIT) cells in pediatric cystic fibrosis (CF) patients. It shows that ETI significantly increases the number of MAIT cells and enhances their production of key cytokines like IFN-g, TNF-a, GrzB, and IL-17A. It is reported that this restoration may help improve infection control in CF patients by bolstering MAIT cell function.
- Subjects :
- CYSTIC fibrosis
T cells
MONONUCLEAR leukocytes
TOXIC shock syndrome
GRANZYMES
Subjects
Details
- Language :
- English
- ISSN :
- 1073449X
- Volume :
- 210
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- American Journal of Respiratory & Critical Care Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 178439298
- Full Text :
- https://doi.org/10.1164/rccm.202401-0201LE